US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Through their two segments, Medline Brand and Supply Chain Solutions, they offer approximately 335,000 med-surg products.</li>
<li>They had net sales of $21.4  billion, $23.2 billion, and $25.5 billion and net income (loss) of ($25 million), $234 million, and $1.2 billion in 2022, 2023, and 2024, respectively.</li>
<li>This company is a staple to the healthcare and hospitals industry and we anticipate a market cap north of $50 billion.</li>
</ul>


Through their two segments, Medline Brand and Supply Chain Solutions, they offer approximately 335,000 med-surg products.
They had net sales of $21.4  billion, $23.2 billion, and $25.5 billion and net income (loss) of ($25 million), $234 million, and $1.2 billion in 2022, 2023, and 2024, respectively.
This company is a staple to the healthcare and hospitals industry and we anticipate a market cap north of $50 billion.


Medline Inc. (MDLN): Peeking at the IPO Prospectus of Mega Hospitals Product & Supply Chain Company

Index Rebalance and Special Situations Coverage, Quiddity Advisors

Anjana Amarasuriya

Index Rebalance and Special Situations Coverage

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>The Nasdaq 100 index tracks the 100 largest names listed on the Nasdaq Stock Exchange.</li>
<li>One active M&amp;A deal could trigger an intra-review ADD. Shareholders have already approved the deal.</li>
<li>We expect three changes and around US$5bn one-way flow for Nasdaq 100 in the June index rebal event and another $2bn in one-way flows on the intra-review change.</li>
</ul>


The Nasdaq 100 index tracks the 100 largest names listed on the Nasdaq Stock Exchange.
One active M&amp;A deal could trigger an intra-review ADD. Shareholders have already approved the deal.
We expect three changes and around US$5bn one-way flow for Nasdaq 100 in the June index rebal event and another $2bn in one-way flows on the intra-review change.


Quiddity Leaderboard Nasdaq100 Jun26 Rebal: Three Regular ADDs/DELs; US$7bn in One-Way Flows

<ul>
<li>Medtronic spinoff with $2.7B FY2025 revenue, global footprint, and blue-chip underwriters targeting a potential Q1 IPO.</li>
<li>Only fully integrated Smart Dosing ecosystem, strengthening competitive moat and positioning the story well for public-market investors.</li>
<li>Exposure to a $18B+ diabetes market growing 10%+ CAGR, with next-generation AID launches supporting an attractive Q1 IPO thesis.</li>
</ul>


Medtronic spinoff with $2.7B FY2025 revenue, global footprint, and blue-chip underwriters targeting a potential Q1 IPO.
Only fully integrated Smart Dosing ecosystem, strengthening competitive moat and positioning the story well for public-market investors.
Exposure to a $18B+ diabetes market growing 10%+ CAGR, with next-generation AID launches supporting an attractive Q1 IPO thesis.


MiniMed Group, Inc. (MMED): Peeking at the IPO Prospectus of Medtronic's Diabetes Spin-Off

<ul>
<li>Andersen priced at the high end and delivered a powerful first-day performance, signaling strong institutional demand despite recent IPO market skepticism.</li>
<li>Shares climbed steadily throughout the session, reflecting high-quality long-only participation and confidence in Andersen’s growth and margin profile.</li>
<li>Near-Term upside may moderate as investors take profits into year-end, but fundamentals support continued longer-term interest.</li>
</ul>


Andersen priced at the high end and delivered a powerful first-day performance, signaling strong institutional demand despite recent IPO market skepticism.
Shares climbed steadily throughout the session, reflecting high-quality long-only participation and confidence in Andersen’s growth and margin profile.
Near-Term upside may moderate as investors take profits into year-end, but fundamentals support continued longer-term interest.


Andersen Group Inc. (ANDG): Professional Services Platform Delivers Strong IPO Debut

United States

Medline Industries is a medical supply company, manufacturer and distributor.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Medline (MDLN US)

Medline Inc. (MDLN): Peeking at the IPO Prospectus of Mega Hospitals Product & Supply Chain Company

Medline, a key player in healthcare, offers a wide range of medical products and is projected to reach a market cap exceeding $50 billion.

IPO Boutique

Quiddity Leaderboard Nasdaq100 Jun26 Rebal: Three Regular ADDs/DELs; US$7bn in One-Way Flows

Three expected changes in the June 2026 Nasdaq 100 rebalance, an active M&A deal in play, and a SpaceX inclusion expected by late July.

Anjana Amarasuriya

MiniMed Group, Inc. (MMED): Peeking at the IPO Prospectus of Medtronic's Diabetes Spin-Off

Medtronic spinoff poised for Q1 IPO with $2.7B revenue, global presence, and innovative Smart Dosing ecosystem targeting the growing diabetes market.

IPO Boutique

Andersen Group Inc. (ANDG): Professional Services Platform Delivers Strong IPO Debut

Andersen delivers a strong IPO debut with steady aftermarket performance. Profit-taking may temper near-term gains, but long-term interest remains...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Medline Inc. (MDLN): Peeking at the IPO Prospectus of Mega Hospitals Product & Supply Chain Company

​Medline, a key player in healthcare, offers a wide range of medical products and is projected to reach a market cap exceeding $50 billion.

IPO Boutique

Quiddity Leaderboard Nasdaq100 Jun26 Rebal: Three Regular ADDs/DELs; US$7bn in One-Way Flows

Three expected changes in the June 2026 Nasdaq 100 rebalance, an active M&A deal in play, and a SpaceX inclusion expected by late July.

Anjana Amarasuriya

MiniMed Group, Inc. (MMED): Peeking at the IPO Prospectus of Medtronic's Diabetes Spin-Off

​Medtronic spinoff poised for Q1 IPO with $2.7B revenue, global presence, and innovative Smart Dosing ecosystem targeting the growing diabetes market.

IPO Boutique

Andersen Group Inc. (ANDG): Professional Services Platform Delivers Strong IPO Debut

​Andersen delivers a strong IPO debut with steady aftermarket performance. Profit-taking may temper near-term gains, but long-term interest remains...

IPO Boutique

Medline, a key player in healthcare, offers a wide range of medical products and is projected to reach a market cap exceeding $50 billion.

Medtronic spinoff poised for Q1 IPO with $2.7B revenue, global presence, and innovative Smart Dosing ecosystem targeting the growing diabetes market.

Andersen delivers a strong IPO debut with steady aftermarket performance. Profit-taking may temper near-term gains, but long-term interest remains...